skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
As chronic hepatitis C virus (HCV) drug development approaches the end-game following the launch of the first pan-genotypic regimen Epclusa ([sofosbuvir + velpatasvir]; Gilead), recent and upcoming advances in chronic hepatitis B virus (HBV) treatment emerged as an important focus of the International Liver Conference (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL), which took place in Amsterdam, the Netherlands, on 19–23 April 2017.

In this report we summarize several notable highlights from this year’s EASL conference. Also included are key abstracts featuring commentary from Biomedtracker and Datamonitor Healthcare analysts including any changes in Likelihood of Approval (LOA), if applicable.
post easl report

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: